

hallmark feature of type 2 diabetes mellitus (T2DM) is the accumulation of islet amyloid polypeptide fibrils in pancreatic islets. Such accumulations form amyloid plaques, referred to as islet amyloidosis. Amyloidosis due to aggregation of amyloid- β is key pathogenic event in AD, whereas aggregation of mature islet amyloid polypeptide (IAPP₃₇) in human islet leads to β -cell dysfunction. Researchers at NIA used a bioinformatic approach to identify two novel islet amyloid polypeptide isoforms: IAPP β , encoding an elongated propeptide and non-aggregating IAPP γ , which is processed to mature IAPP₂₅ instead of IAPP₃₇. They developed a quantitative selective reaction monitoring (SRM) proteomic assay to measure the isoform peptide levels in human clinical plasma and CSF from individuals with early AD and found that their levels were significantly reduced. Further, mature IAPP₂₅ derived from IAPP γ isoform inhibits fibrillation of IAPP and amyloid- β efficiently *in vitro*.

Potential Commercial Applications: The novel IAPP β and IAPP γ isoforms are potential peptidyl therapeutics to counteract with amyloid forming IAPP and amyloid- β in treatments of diabetes and Alzheimer's disease and serve as blood-based biomarkers for Alzheimer's disease.

Competitive Advantages:

- Peptide based anti-amyloid medicine.
- Potential market applications for neurodegenerative diseases.

Development Stage: Pre-clinical (*in vivo* validation).

Publications: Liu, Q.-R., et al. Novel Hominid-Specific IAPP Isoforms: Potential Biomarkers of Early Alzheimer's Disease and Inhibitors of Amyloid Formation. (PMID 36671553) at <https://pubmed.ncbi.nlm.nih.gov/36671553/>.

Meng, Lanxia, et al. Islet amyloid polypeptide triggers α -synuclein pathology in Parkinson's disease. (PMID 37150314)

Dated: August 11, 2023.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2023-17673 Filed 8-16-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Human Genome Research Institute; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Human Genome Research Institute Initial Review Group; Genome Research Study Section GNOM—G—CEGS.

Date: November 2–3, 2023.

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Room 3180, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Sarah Jo Wheelan, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 6700B Rockledge Drive, Room 3180, Bethesda, MD 20892, (301) 402-8823, wheelansj@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS)

Dated: August 14, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-17713 Filed 8-16-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Mental Health.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section

552b(c)(6), title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute Of Mental Health, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors; National Institute of Mental Health.

Date: September 20–22, 2023.

Time: September 20, 2023, 1:00 p.m. to 5:15 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892.

Time: September 21, 2023, 10:00 a.m. to 5:55 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892.

Time: September 22, 2023, 10:00 a.m. to 3:10 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Bethesda, MD 20892.

Contact Person: Jennifer E. Mehren, Ph.D., Scientific Advisor, Division of Intramural Research Programs, National Institute of Mental Health, NIH, 35A Convent Drive, Room GE 412, Bethesda, MD 20892-3747, 301-496-3501, mehrenj@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)

Dated: August 14, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-17711 Filed 8-16-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Collaboration Opportunity To Develop a Vaccine Against Nicotine or Arecoline

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The Cancer Prevention Program of the National Cancer Institute (NCI) is seeking a partner in the private